First clinical trials on potent new hepatitis C drug successfully completed
September 4th, 2010 - 6:06 pm ICT by ANIWashington, Sep 4 (ANI): Scientists have successfully completed the first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus.
INX-189, which is still in the initial stages, is being considered better than current treatment drugs- ribavirin and interferon, whose side effects are often severe.
Professor Chris McGuigan of the Welsh School of Pharmacy, academic lead on the project, said: “The efficiency of drug release in this study has also confirmed that one single dose a day is most likely enough in treating the virus”.
“We believe that INX-189 offers the possibility of more potency against Hepatitis, more rapid action in the liver, and fewer side effects than existing treatments,” he added.
The research undertaken by Cardiff University showed INX-189 killed 90 per cent of the virus at very low (nanomolar) concentration, making it the most potent compound of its kind developed to date.
Approximately 170 million people worldwide are affected with Hepatitis C, which can lead to liver cancer, cirrhosis and death.
The research undertaken by Cardiff University showed INX-189 killed 90 per cent of the virus at very low (nanomolar) concentration, making it the most potent compound of its kind developed to date. (ANI)
- Trials start on potent new hepatitis C drug - May 15, 2010
- Trials begin on potent new Hepatitis C drug - May 15, 2010
- Clinical trial offers hope for Hepatitis C patients - Mar 15, 2011
- Coffee can cure hepatitis C - Jun 08, 2011
- Healing damaged liver tissues - Dec 05, 2011
- Success of hepatitis C treatment may depend on genetic variant - Jun 13, 2010
- Drug cocktail shows promise against hepatitis C - Mar 31, 2011
- Experimental hepatitis C drug shows promise - Dec 04, 2009
- New hope for hepatitis C sufferers - Apr 09, 2010
- Extended hepatitis C treatment after liver transplant beneficial for patients - May 03, 2010
- Biomarker that predicts response to hepatitis C treatment identified - Aug 17, 2009
- Coffee may be good for chronic hepatitis C patients - Oct 21, 2009
- How interferon-induced genes launch antiviral defenses - Apr 11, 2011
- Extending hepatitis C treatment for liver transplant patients may be beneficial - Nov 01, 2009
- New therapy could help beat Hepatitis C virus - Jan 17, 2012
Tags: cardiff university, cirrhosis, clinical trials, concentration, hepatitis, hepatitis c, hepatitis c virus, initial stages, interferon, investigational drug, liver cancer, mcguigan, potency, potent compound, professor chris, rapid action, ribavirin, school of pharmacy, treatment drugs, welsh school